目的系统评价补充益生菌对儿童过敏性湿疹的预防效果。方法运用Rev Man 5.3软件,对2000年以来国内外发表的有关益生菌预防儿童过敏性湿疹的随机对照试验研究进行Meta分析,根据异质性检验结果选择固定效应模型或随机效应模型,计算RR值及9...目的系统评价补充益生菌对儿童过敏性湿疹的预防效果。方法运用Rev Man 5.3软件,对2000年以来国内外发表的有关益生菌预防儿童过敏性湿疹的随机对照试验研究进行Meta分析,根据异质性检验结果选择固定效应模型或随机效应模型,计算RR值及95%CI,评估发表偏倚,进行敏感性分析,并按干预菌株不同及随访时间点不同进行亚组分析。结果最终纳入23篇文献,累计干预组3 004例,对照组3 016例。合并效应量结果显示,益生菌预防儿童过敏性湿疹的合并RR值为0.76(95%CI:0.65~0.89)(P<0.05);亚组分析结果显示,使用混合菌株干预效果显著(RR=0.56,95%CI:0.41~0.78)(P<0.05),随访时间≤12个月及≤24个月所得结果表明益生菌预防儿童过敏性湿疹效果显著(P<0.05),合并RR值分别为0.69(95%CI:0.51~0.93)和0.77(95%CI:0.60~0.98)。结论应提倡孕期及婴幼儿期补充益生菌,推荐使用乳酸杆菌和双歧杆菌混合菌株,预防儿童过敏性湿疹。展开更多
The skin facilitates a number of key roles but its functioning can be impaired by disease. Atopic eczema is a chronic inflammatory disease where the skin barrier has become leaky, and inflammation occurs. It affects u...The skin facilitates a number of key roles but its functioning can be impaired by disease. Atopic eczema is a chronic inflammatory disease where the skin barrier has become leaky, and inflammation occurs. It affects up to 20% of children and 3% of adults worldwide, manifesting as red itchy patches of skin with varying severity. This review aims to investigate the leaky skin barrier and immune mechanisms from the perspective of potential novel treatments. The complexity of atopic eczema as a disease is what makes it difficult to treat. Genome-wide association studies have highlighted possible genetic variations associated with atopic eczema, however in some cases, individuals develop the disease without these genetic risk factors. Loss of function mutations in the filaggrin gene are one of these associations and this is plausible due to its key role in barrier function. The Th2 immune response is the link with regards to the immune mechanisms as atopic inflammation often occurs through increased levels of interleukin(IL)-4 and IL-13. Eczematous inflammation also creates susceptibility to colonisation and damage by bacteria such as Staphylococcus aureus. Potential novel treatments are becoming ever more specific, offering the hope of fewer side effects and better disease control. The best new treatments highlighted in this review target the immune response with human beta defensin 2, phosphodiesterase-4 inhibitors and monoclonal antibodies all showing promise.展开更多
文摘目的系统评价补充益生菌对儿童过敏性湿疹的预防效果。方法运用Rev Man 5.3软件,对2000年以来国内外发表的有关益生菌预防儿童过敏性湿疹的随机对照试验研究进行Meta分析,根据异质性检验结果选择固定效应模型或随机效应模型,计算RR值及95%CI,评估发表偏倚,进行敏感性分析,并按干预菌株不同及随访时间点不同进行亚组分析。结果最终纳入23篇文献,累计干预组3 004例,对照组3 016例。合并效应量结果显示,益生菌预防儿童过敏性湿疹的合并RR值为0.76(95%CI:0.65~0.89)(P<0.05);亚组分析结果显示,使用混合菌株干预效果显著(RR=0.56,95%CI:0.41~0.78)(P<0.05),随访时间≤12个月及≤24个月所得结果表明益生菌预防儿童过敏性湿疹效果显著(P<0.05),合并RR值分别为0.69(95%CI:0.51~0.93)和0.77(95%CI:0.60~0.98)。结论应提倡孕期及婴幼儿期补充益生菌,推荐使用乳酸杆菌和双歧杆菌混合菌株,预防儿童过敏性湿疹。
文摘The skin facilitates a number of key roles but its functioning can be impaired by disease. Atopic eczema is a chronic inflammatory disease where the skin barrier has become leaky, and inflammation occurs. It affects up to 20% of children and 3% of adults worldwide, manifesting as red itchy patches of skin with varying severity. This review aims to investigate the leaky skin barrier and immune mechanisms from the perspective of potential novel treatments. The complexity of atopic eczema as a disease is what makes it difficult to treat. Genome-wide association studies have highlighted possible genetic variations associated with atopic eczema, however in some cases, individuals develop the disease without these genetic risk factors. Loss of function mutations in the filaggrin gene are one of these associations and this is plausible due to its key role in barrier function. The Th2 immune response is the link with regards to the immune mechanisms as atopic inflammation often occurs through increased levels of interleukin(IL)-4 and IL-13. Eczematous inflammation also creates susceptibility to colonisation and damage by bacteria such as Staphylococcus aureus. Potential novel treatments are becoming ever more specific, offering the hope of fewer side effects and better disease control. The best new treatments highlighted in this review target the immune response with human beta defensin 2, phosphodiesterase-4 inhibitors and monoclonal antibodies all showing promise.
